Checkmate Pharmaceuticals, Inc.

CAMBRIDGE, MA
Create Email Alert

Checkmate Pharmaceuticals is based out of Cambridge. Checkmate Pharmaceuticals, Inc. operates as a biotechnology company. The Company discovers and develops novel approaches for cancer immunotherapy such as immuno-oncology. Checkmate Pharmaceuticals serves patients worldwide. The firm last filed a Form D notice of exempt offering of securities on 2020-06-18. The notice included securities offered of Equity

Contact Info

checkmate pharmaceuticals, inc.
245 MAIN STREET, 2ND FLOOR
CAMBRIDGE MA    02142

Business Phone: 978-503-2124
SEC SIC CODE:
2836-BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Active Schedule 13D and 13G events

Sign in to see

Insider Transactions in the past year

Loading...

Form D Filings

Form D is a form used to file a notice of an exempt offering of securities with the Securities and Exchange Commission. Form D contains basic information about the offering and the company.

Form D Filings
Filing Date Form Type Industry Group Securities Offered Total Offering Amount Total Amount Sold Total Remaining
2020-06-18 D BIOTECHNOLOGY Equity 100,083,274 85,083,280 14,999,994
2020-04-24 D BIOTECHNOLOGY Debt 10,000,000 10,000,000 0
2020-01-28 D/A BIOTECHNOLOGY Equity 15,999,999 15,999,999 0
2019-08-20 D BIOTECHNOLOGY Equity 15,999,999 7,999,996 8,000,003
2019-04-01 D/A BIOTECHNOLOGY Equity 21,999,995 21,999,995 0
2018-12-12 D BIOTECHNOLOGY Equity 21,999,995 10,999,998 10,999,997
2017-06-16 D BIOTECHNOLOGY Equity 27,000,000 27,000,000 0
2017-02-16 D/A BIOTECHNOLOGY Equity 25,000,000 25,000,000 0
2016-06-30 D/A BIOTECHNOLOGY Equity 20,000,000 20,000,000 0
2015-08-25 D PHARMACEUTICALS Equity,Option, Warrant or Other Right to Acquire Another Security,Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security 20,030,000 10,030,000 10,000,000
Other Issuers in Filings
Name Address
No Other Issuers
Related Parties included in filings
Name Address Relationship
ARTHUR A. KRIEG subscription required
    EXECUTIVE OFFICER DIRECTOR
MICHAEL POWELL subscription required
    DIRECTOR
COREY GOODMAN subscription required
    DIRECTOR
CHUCK ABDALIAN subscription required
    EXECUTIVE OFFICER
BEN AUSPITZ subscription required
    DIRECTOR
CHARLES ABDALIAN subscription required
    EXECUTIVE OFFICER
DAVID MAURO subscription required
    EXECUTIVE OFFICER
RAMANI VARANASI subscription required
    EXECUTIVE OFFICER
CHARLES YON subscription required
    EXECUTIVE OFFICER
ART KRIEG subscription required
    EXECUTIVE OFFICER DIRECTOR
KAREN BRENNAN subscription required
    EXECUTIVE OFFICER
BARRY LABINGER subscription required
    EXECUTIVE OFFICER DIRECTOR
JON LIEBER subscription required
    EXECUTIVE OFFICER
KEITH FLAHERTY subscription required
    DIRECTOR
ALAN FUHRMAN subscription required
    DIRECTOR
JONATHAN LIEBER subscription required
    EXECUTIVE OFFICER
JAMES WOOLDRIDGE subscription required
    EXECUTIVE OFFICER
KLEEM CHAUDHARY subscription required
    EXECUTIVE OFFICER
PETER COLABUONO subscription required
    DIRECTOR
ROBERT WEISSKOFF subscription required
    DIRECTOR

Elevate your investments